Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Relapse is the main cause of treatment failure for leukaemia patients with unfavourable gene mutations who receive allogeneic haematopoietic stem cell transplantation (allo‐HSCT). There is no consensus on the indication of donor lymphocyte infusion (DLI) for prophylaxis of relapse after allo‐HSCT. T...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Zhang, Rui, Wang, Lili, Chen, Peng, Gao, Xiaoning, Wang, Shuhong, Li, Fei, Dou, Liping, Gao, Chunji, Li, Yan, Liu, Daihong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2021
Gaiak:
Clinical Cancer Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124122/
https://ncbi.nlm.nih.gov/pubmed/33932107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3763
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak